<DOC>
	<DOCNO>NCT00191984</DOCNO>
	<brief_summary>A non-randomized phase II study determine efficacy safety combination Pemetrexed Irinotecan every two week metastatic colorectal cancer patient .</brief_summary>
	<brief_title>A Study Combination Pemetrexed Irinotecan Every Two Weeks Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis metastatic colorectal adenocarcinoma amenable curative therapy . Patient must least one unidimensionally measurable lesion . Prior radiation therapy le 25 % bone marrow . Radiation must complete least 4 week prior study enrollment . Performance status 0 2 Patient must receive 1 prior course chemotherapy ( Folfox regimen ) metastatic disease Treatment drug within last 30 day receive regulatory approval . Serious systemic disorder ( cardiac pulmonary disease , active infection ) Documented brain metastasis amenable surgery unstable radiation Inability unwillingness take folic acid Vitamin B12 supplementation . Presence fluid retention control drainage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>